Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 207
Rating:

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA

Prof Debu Tripathy speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the MONALEESA-7 trial, which examined the combination of ribociclib and endocrine therapy in premenopausal patients with metastatic breast cancer.

He states that this drug combination roughly doubled progression-free survival and statistically significant survival benefit in these patients.

Prof Tripathy discusses future work for this trial, which includes analysing both tissue and blood specimens from this patient population, which may be correlated with improved survival and therefore help direct new research.


 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation